# ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma

Source: https://onco.cc/trials/nct04634357/  
OnCo record `nct04634357` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ET140203 T Cells in hepatoblastoma and hepatocellular carcinoma, run by Eureka Therapeutics Inc., now recruiting.

## Summary

ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma is a phase 1/2 interventional study registered as NCT04634357 by Eureka Therapeutics Inc., with 12 participants planned, started 2022-07-19 and due to reach its primary completion in 2027-12-31. Interventions recorded: ET140203 T Cells.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04634357
- Phase: 1/2
- Setting: An Open-Label, Dose Escalation, Phase I/II Clinical Trial of ET140203 T Cells in Pediatric Subjects With Relapsed/Refractory Hepatoblastoma (HB), Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS), or Hepatocellular Carcinoma (HCC)
- Sponsor: Eureka Therapeutics Inc.
- Enrolled: 12

## Sources

- ClinicalTrials.gov NCT04634357: https://clinicaltrials.gov/study/NCT04634357

## Connected records

- cancers: [Hepatoblastoma](https://onco.cc/cancers/hepatoblastoma/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)

---
JSON: https://onco.cc/api/v1/entities/nct04634357.json